Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA disease redefinition proposal marks "profound policy change," Israelsen maintains.

This article was originally published in The Tan Sheet

Executive Summary

FDA DISEASE REDEFINITION PROPOSAL A "PROFOUND" POLICY CHANGE, LDI Group President Loren Israelsen asserted at a nutraceuticals meeting in New York City May 20-21. The agency's April 29 proposed rule on allowable dietary supplement structure/function claims blurs the distinction between "disease" and "health condition," Israelsen maintained. The importance of the proposed redefinition of disease is being slighted by the industry, when, in fact, it "is a profound change of thinking and policy within FDA," he added. The meeting was sponsored by the Foundation for Innovation in Medicine.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel